Literature DB >> 11121825

A review of randomized, controlled clinical trials in acute mania.

P E Keck1, J Mendlwicz, J R Calabrese, J Fawcett, T Suppes, P A Vestergaard, C Carbonell.   

Abstract

This review considers the evidence supporting the use of somatic therapies (medications and electroconvulsive therapy) in the treatment of acute mania associated with bipolar disorder. Data from randomized, controlled clinical trials have established the efficacy of lithium, divalproex sodium, and carbamazepine in the treatment of acute mania. The use of combinations of mood stabilizers in the treatment of acute mania has not been well examined in controlled trials. Conventional antipsychotics and some atypical antipsychotics are frequently used as initial or adjunctive treatment. Similarly, benzodiazepines are frequently used as adjunctive agents. Preliminary data suggest that some calcium channel blockers and several anticonvulsants, e.g., lamotrigine, gabapentin, and topiramate, may have therapeutic value in the treatment of acute mania. In contrast, electroconvulsive therapy is generally accepted as being highly effective despite the lack of controlled evidence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121825     DOI: 10.1016/s0165-0327(00)00177-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

1.  The management of acute mania.

Authors:  Paul E Keck
Journal:  BMJ       Date:  2003-11-01

2.  Diagnosis and management of patients with bipolar disorder in primary care.

Authors:  Michael Berk; Seetal Dodd; Lesley Berk; Jane Opie
Journal:  Br J Gen Pract       Date:  2005-09       Impact factor: 5.386

Review 3.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms.

Authors:  Alan G Mallinger; Michael E Thase; Roger Haskett; Joan Buttenfield; David A Luckenbaugh; Ellen Frank; David J Kupfer; Husseini K Manji
Journal:  Bipolar Disord       Date:  2008-12       Impact factor: 6.744

Review 5.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 6.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania.

Authors:  Amir Akhavan Rezayat; Paria Hebrani; Fatemeh Behdani; Mohamad Salaran; Majid Nabizadeh Marvast
Journal:  J Res Med Sci       Date:  2014-08       Impact factor: 1.852

8.  Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study.

Authors:  Massimo Pasquini; Angelo Picardi; Azzurra Speca; Valerio Orlandi; Lorenzo Tarsitani; Pierluigi Morosini; Isabella Cascavilla; Massimo Biondi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-02-08

9.  Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

Authors:  Xianbin Li; Yilang Tang; Chuanyue Wang
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.